Details for New Drug Application (NDA): 209714
✉ Email this page to a colleague
The generic ingredient in FULVESTRANT is fulvestrant. There are twelve drug master file entries for this compound. Twenty-one suppliers are listed for this compound. Additional details are available on the fulvestrant profile page.
Summary for 209714
| Tradename: | FULVESTRANT |
| Applicant: | Hbt Labs Inc |
| Ingredient: | fulvestrant |
| Patents: | 0 |
Pharmacology for NDA: 209714
| Mechanism of Action | Estrogen Receptor Antagonists Selective Estrogen Receptor Modulators |
Suppliers and Packaging for NDA: 209714
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| FULVESTRANT | fulvestrant | SOLUTION;INTRAMUSCULAR | 209714 | ANDA | Meitheal Pharmaceuticals Inc | 71288-555 | 71288-555-86 | 2 SYRINGE in 1 CARTON (71288-555-86) / 5 mL in 1 SYRINGE (71288-555-85) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | SOLUTION;INTRAMUSCULAR | Strength | 250MG/5ML (50MG/ML) | ||||
| Approval Date: | Nov 21, 2019 | TE: | AO | RLD: | No | ||||
Complete Access Available with Subscription
